CeriBell (CBLL) Competitors $12.18 -0.13 (-1.06%) Closing price 04:00 PM EasternExtended Trading$12.18 +0.01 (+0.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CBLL vs. EYE, AORT, LQDA, CNMD, ENOV, SSII, NVCR, CDRE, BLFS, and MDXGShould you be buying CeriBell stock or one of its competitors? The main competitors of CeriBell include National Vision (EYE), Artivion (AORT), Liquidia Technologies (LQDA), CONMED (CNMD), Enovis (ENOV), SS Innovations International (SSII), NovoCure (NVCR), Cadre (CDRE), BioLife Solutions (BLFS), and MiMedx Group (MDXG). These companies are all part of the "medical equipment" industry. CeriBell vs. Its Competitors National Vision Artivion Liquidia Technologies CONMED Enovis SS Innovations International NovoCure Cadre BioLife Solutions MiMedx Group CeriBell (NASDAQ:CBLL) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Do analysts prefer CBLL or EYE? CeriBell presently has a consensus price target of $32.14, indicating a potential upside of 164.14%. National Vision has a consensus price target of $24.73, indicating a potential upside of 3.48%. Given CeriBell's stronger consensus rating and higher probable upside, equities research analysts plainly believe CeriBell is more favorable than National Vision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CeriBell 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00National Vision 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has preferable earnings & valuation, CBLL or EYE? National Vision has higher revenue and earnings than CeriBell. National Vision is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCeriBell$65.44M6.82-$40.46M-$2.99-4.07National Vision$1.82B1.04-$28.50M-$0.18-132.76 Is CBLL or EYE more profitable? National Vision has a net margin of -0.75% compared to CeriBell's net margin of -63.83%. National Vision's return on equity of 3.56% beat CeriBell's return on equity.Company Net Margins Return on Equity Return on Assets CeriBell-63.83% -48.42% -28.50% National Vision -0.75%3.56%1.49% Does the media favor CBLL or EYE? In the previous week, National Vision had 2 more articles in the media than CeriBell. MarketBeat recorded 4 mentions for National Vision and 2 mentions for CeriBell. National Vision's average media sentiment score of 1.48 beat CeriBell's score of 0.51 indicating that National Vision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive National Vision 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNational Vision beats CeriBell on 8 of the 13 factors compared between the two stocks. Get CeriBell News Delivered to You Automatically Sign up to receive the latest news and ratings for CBLL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBLL vs. The Competition Export to ExcelMetricCeriBellMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$446.12M$10.48B$5.70B$9.79BDividend YieldN/A1.90%3.77%4.10%P/E Ratio-4.0720.6330.8625.25Price / Sales6.8233.19403.9088.50Price / CashN/A24.9525.2228.45Price / Book2.283.459.516.00Net Income-$40.46M$209.94M$3.26B$265.34M7 Day Performance0.40%3.88%4.49%2.81%1 Month Performance-21.89%12.50%5.18%1.50%1 Year PerformanceN/A-9.26%31.98%25.46% CeriBell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBLLCeriBell2.3265 of 5 stars$12.18-1.1%$32.14+163.9%N/A$446.52M$65.44M-4.07N/AEYENational Vision2.6348 of 5 stars$22.77+0.6%$24.73+8.6%+104.4%$1.79B$1.82B-126.5213,411Positive NewsAORTArtivion3.344 of 5 stars$43.05+5.1%$40.00-7.1%+70.8%$1.75B$388.54M-102.511,600Analyst DowngradeHigh Trading VolumeLQDALiquidia Technologies3.493 of 5 stars$21.20+3.7%$26.89+26.8%+83.9%$1.75B$14M-13.4250News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionCNMDCONMED4.3473 of 5 stars$52.53-3.9%$59.80+13.8%-21.2%$1.69B$1.31B14.883,900ENOVEnovis3.922 of 5 stars$28.15-1.0%$51.00+81.2%-33.0%$1.63B$2.11B-1.987,367SSIISS Innovations InternationalN/A$6.25-7.7%N/AN/A$1.31B$20.65M0.004Gap DownNVCRNovoCure3.9747 of 5 stars$10.90-2.1%$28.79+164.1%-34.5%$1.24B$605.22M-6.991,488Positive NewsCDRECadre1.7151 of 5 stars$28.48-6.8%$37.50+31.7%-16.3%$1.24B$567.56M30.302,284BLFSBioLife Solutions3.3868 of 5 stars$22.37-1.4%$31.29+39.9%-5.8%$1.09B$82.25M-186.40440Positive NewsHigh Trading VolumeMDXGMiMedx Group3.1983 of 5 stars$7.04+0.3%$12.00+70.5%+13.6%$1.04B$348.88M33.53870Positive News Related Companies and Tools Related Companies National Vision Alternatives Artivion Alternatives Liquidia Technologies Alternatives CONMED Alternatives Enovis Alternatives SS Innovations International Alternatives NovoCure Alternatives Cadre Alternatives BioLife Solutions Alternatives MiMedx Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBLL) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CeriBell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CeriBell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access